FGFR突变对癌症免疫治疗和肿瘤微环境的临床意义：一项泛癌症研究

Clinical Implications of FGFR Mutations for Cancer Immunotherapy and Tumor Microenvironment: A Pan-Cancer Study

摘要: 目的：探讨成纤维细胞生长因子受体(FGFRs)在多种癌症中的作用。方法：从TCGA泛癌数据中获得了33种癌症中FGFRs (FGFR1、FGFR2、FGFR3、FGFR4)的基因表达和临床数据，以及它们与肿瘤微环境(TME)的关联，此外，从cBioPortal数据获得了1661例接受免疫治疗的癌症患者的临床数据。结果：FGFRs在不同肿瘤类型中的表达存在明显差异，且与患者的总生存期相关。FGFRs与免疫浸润亚型、间质细胞浸润水平和肿瘤干细胞显著相关。并且FGFRs突变被证实与高TMB相关。FGFRs突变患者接受免疫检查点抑制剂(ICIs)治疗的总生存(OS)较好(FGFRs: P = 0.0096)。最后，我们建立了一个新的列线图来预测接受ICIs治疗的癌症患者的预后。结论：我们的系统预后列线图显示出预测ICIs治疗预后的巨大潜力。

Abstract: Objective: To investigate the effect of Fibroblast growth factor receptors (FGFRs) in multiple forms of cancer. Method: Gene expression and clinical data of FGFRs (FGFR1, FGFR2, FGFR3, FGFR4) and their association with tumor microenvironment (TME) in 33 cancer types were obtained from the TCGA pan-cancer data. Moreover, clinical and response data of 1661 cancer patients who received immunotherapy were downloaded from cBioPortal database. Result: The expression of FGFRs was significantly different in different cancer types, and it was related to the overall survival of patients. In addition, FGFRs were significant correlated with immune infiltrate subtypes, the level of stromal cell infiltration and tumor stem cells. The mutation of FGFRs was confirmed to be associated with TMB. Moreover, patients with FGFRs mutations had a better overall survival (OS) to immune checkpoint inhibitors (ICIs) treatment (FGFRs: P = 0.0096). We built a novel nomogram to predict the prognosis of cancer patients with ICIs treatment. Conclusion: Our systematic prognostic nomo-gram showed a great potential to predict the prognosis of ICIs treatment.